The 50 index ushered in the first adjustment of the three pharmaceutical companies into.

On August 28th the Shanghai Stock Exchange and China Securities Index Co., Ltd. will adjust the sample of the 50 index according to the index rules.
The index adjustment plan to replace 5 stocks: Weisheng Information, Uxter, Ze-Yuan Pharmaceuticals, Tebao Bio, Bohai Sheng Branch will be transferred into the index, in contrast to the new photoelectrelectrical, thermal scene biology, Hongquan Materials Union, United New Materials, Platinum 5 stocks were transferred out.
addition, in order to improve the predictability and transparency of the interim adjustment of the index, five stocks, including Sussaic Bio, were added as alternative lists to prevent temporary conditions between adjustments.
note that there are a significant number of biopharmaceutical companies in this adjustment, both in the transfer-out and on the alternative list.
01 transfer in and out, all have the pharmaceutical board 50 component index is composed of the large market value of the board, good liquidity of 50 stocks, the use of component index way to focus on reflecting the market performance of the tablet.
50 Index was officially released on July 22 this year, the first anniversary of the establishment of the Science and Trot Board.
the establishment of the total market value of the 50 index accounted for 30% of the board, operating profit, home-made net profit accounted for nearly 70% of the core assets of the board can be said to be the representative.
as of August 21st, the market capitalisation of the Kotseng 50 Index accounted for 37.01 per cent of the total market capitalisation of the Kotseng Board, and the market capitalisation of the Kotseng Board accounted for 50.95 per cent of the market capitalisation of the Kotseng Board.
the proportion of market capitalization, the 50 index also shows good representation in the distribution of the industry.
In the science and technology (computer, electronics), biomedical enterprises in the circulation market value accounted for more than 70% of the overall, and in the Science and Technology 50 Index, the weight of these three sub-sectors is also more than 70%, showing distinct characteristics of scientific and technological innovation.
specific to the pharmaceutical sector, before the adjustment of the technology 50 index a total of 8 biopharmaceutical stocks, respectively, hot scene biology, Shenlian biology, micro-core biology.
, Haier Bio, Berry Pharmaceuticals, Nan Micromedical and Huaxi Bio.
Although the number of pharmaceutical stocks selected is less than one-sixth, ranking only fourth among the sub-sectors, but as of the close of the 28th adjustment announcement, the market value of the eight pharmaceutical stocks reached 189.1 billion, the weight of the 50 index in the company accounted for nearly 20%.
excluding Shenlian Bio (with a market capitalisation of about $9.7 billion) and Hotscape Creatures (about $3.2 billion), the remaining six companies have a market capitalisation of more than $10 billion.
this adjustment is a quarterly regular adjustment of the sample stocks of the 50 index.
Due to the large number of stocks listed in the initial stage of the Board, in order to improve the representativeness of the index more timely reflect the overall situation of the Kotseng Board market, the sample stocks of the Kotseng 50 Index are adjusted quarterly in accordance with the rules.
, unlike the semi-annual adjustment cycle of the general index component stocks, the faster frequency of the Kotseng 50 index is also more adapted to the characteristics of the rapid changes in the update of the technology sector.
50 index in the first half of this year achieved a cumulative increase of nearly 50%, strong growth momentum.
performance of the five companies transferred out of the stock market this time is not ideal, including three in the first half of the year showed varying degrees of loss or decline, the representativeness has been weakened.
as of August 28th, the five stocks had a market capitalisation of about $26bn, with most of them worth about $5bn, while the five transferred had a market capitalisation of more than $100bn.
from the point of view of market value, the new five stocks are more in line with the selection requirements of the 50 index sample.
specific to the adjustment involving a number of biopharmaceutical stocks, the index representative further increased.
, which was transferred out of the index, landed on the board on September 30, 2019, raising a total of 288 million yuan, and is currently the smallest IPO financing enterprise in the biopharmaceutical enterprises.
as of the close of trading on August 28th, Hotscape Bio had a market capitalisation of $3.2 billion, while the three biopharmaceutical companies, Zetsu Pharmaceuticals, Tebao Bio and Bohai Bio, had a market capitalisation of $23.3 billion, $21.6 billion and $18.6 billion, respectively.
the top 20 companies in the market capitalization of the Technology Technology Board, Zee-Pharma, Tebao Bio are among them.
In terms of performance, the newly transferred pharmaceutical enterprises are also more representative, Special Bao Bio, Bohai Health Co. in the first half of the net profit of 46.61 million yuan, 27.52 million yuan, respectively, while hot-view bio affected by the outbreak net profit of 1.9534 million yuan, down 82.94 percent year-on-year.
particularly noteworthy is that the transfer of Ze-Yuan Pharmaceuticals is the first unprofitable listed company of the Company, and this transfer is also the first unprofitable stock in the Kotseng 50 Index.
pharmaceutical enterprises are still in their infancy, and the inclusion of unprofitable enterprises in the index can better reflect the characteristics driven by scientific and technological innovation in the biopharmaceutical industry.
Ze-Yuan Pharmaceuticals is an innovative-driven new drug research and development company focused on the field of cancer, bleeding and blood diseases, liver and bile diseases, etc., and was listed on the Board on January 23, 2020, raising a total of 2,026 million yuan.
the first half of 2020 results disclosed by Ze-Yuan Pharmaceuticals, the company did not achieve operating income, net profit loss of 129 million yuan.
, on the other hand, Ze-Yu Pharmaceuticals is still increasing its investment in research and development of new drugs.
financial results show that zealo Pharmaceuticals' product pipeline has 12 major drugs in the study of 30 projects, of which 5 are in the NDA (new drug market application), II/III phase clinical trial stage, 1 in phase I/II clinical trial stage, 1 in the IND stage, 5 in the pre-clinical research and development stage.
first half of 2020, Ze-Yuan Pharmaceuticals invested about 129 million yuan in research and development, an increase of 70.84 percent year-on-year.
This sample adjustment will increase the weighting of biopharmaceutical stocks in the 50 index, can better reflect the structural characteristics of biopharmaceutical stocks in the board, but also can reflect the changes in the stock of the board of biopharmaceuticals for more than a year.
for investors, the adjustment will provide the market with more accurate benchmarks and performance benchmarks for biopharmaceutical companies.
, on the other hand, the first four batch of The 50 Index Fund has been accepted, and as the participation of the Fund increases, the Genesis 50 ETF will bring new incremental funds to the Board.
more biopharmaceutical stocks are being absorbed into the 50 index, which is undoubtedly good news for the biopharmaceutical companies that have landed on the board.
02 34 pharmaceutical stocks with a total market value of more than 660 billion science and technology board was established with the original intention of supporting the development of scientific and technological innovation-oriented enterprises based on scientific and technological power.
more than a year since its establishment, the answers handed over by the Board have been quite bright.
, according to Oriental Wealth Data, as of August 28, the total number of filing companies reached 416.
164 of these companies have been listed for trading.
182 enterprises registered in force, 22 submitted for registration, through the Municipal Committee meeting 8, has asked 159, has accepted 10, 1 enterprise suspended consideration, 31 enterprises terminated the audit.
according to SSE data, as of August 28, the total market value of the 164 companies listed on the board exceeded 2.86 trillion yuan, an increase of more than 500%.
, four companies are in the "100 billion market value club" and 74 companies have a market capitalization of more than 10 billion.
focus on the field of biomedicine, biomedicine has become the second largest field in the science and technology in addition to science and technology.
according to E-Drug Manager statistics, as of August 28, the company has listed 34 biopharmaceutical companies, with a total market value of 663.263 billion yuan, accounting for 23.2% of the total market value of the board.
, the highest market capitalization was Junshi Bio, which had just landed on the board in July, with a total market capitalisation of $62.5 billion.
Huaxi Bio was closely followed by Huaxi Bio with a market capitalisation of $60.7 billion, with both companies squeezing into the top 10 in the market value of the shares.
especially since this year, the biopharmaceutical industry is very active in the branch sector.
The first half of the new crown epidemic put the pharmaceutical and biological industry on the market, pharmaceutical stocks strong performance, and even many enterprises during the outbreak doubled the market value, more than 70% of the market value of more than 70% of the board biopharmaceutical enterprises more than 10 billion.
34 companies also performed well, with total operating income and net profit in the biopharmaceutical industry up 34.61 percent and 2,757.65 percent, respectively, as of Aug. 31, according to the latest report from the Securities Times.
, affected by the increase in epidemic prevention and control and medical needs, the testing reagent company Sanxiang Biological, Shushi Biological, Oriental Biology increased significantly.
biopharmaceutical industry is in line with the positioning properties of the tablet.
the characteristics of scientific and technological innovation, the company has provided a good financing channel for biopharmaceutical enterprises that are still in the research and development stage and need a lot of financial support, especially the innovative pharmaceutical enterprises in the early stages of entrepreneurship.
the future more biopharmaceutical enterprises landing on the board will also provide more opportunities for the development of the pharmaceutical industry in the post-epidemic era.
.